- Completed dosing of three additional patients as an expansion of the first dose cohort of ASPIRO, the Phase 1/2 clinical study of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM)
- Plan to report additional interim data from ASPIRO during an oral presentation at the 21st Annual Meeting of the American Society of Gene and Cell Therapies (ASGCT) on May 16, 2018
- Initial proof of concept established with twelve-week data from the first subject enrolled in VALENS, the Phase 1/2 clinical study of AT342 for the treatment of Crigler-Najjar Syndrome; plan to escalate to higher dose and enroll the next patient in the coming weeks
PR Newswire
SAN FRANCISCO, May 9, 2018
